02.16 Acute Coronary Syndrome Flashcards
Caused by complete obstruction of a coronary artery
STEMI
Results in damage or necrosis of the full thickness of the heart muscles
STEMI
Caused by partial obstruction of a coronary artery
NSTEMI
Resulting necrosis only involves a partial thickness of the heart muscle
NSTEMI
2 main components of atherosclerotic plaques
Soft, lipid-rick core
Hard, collagen-rich fibrous cap
Thick fibrous cap may represent >70% of plaque volume
Stable plaque
Lipid-rich core may represent the majority of the plaque volume
Unstable plaque
Due to inflammation by foam cells and other inflammatory mediators that make the plaque more vulnerable to rupture
Plaque destabilization
Where does plaque destabilization commonly occur
At the junction of the plaque and the less diseased vessel wall
Primary cause of a heart attack
Rupture of unstable plaques
Usually >20 minutes in duration
Sudden chest pain patient is at rest
Rest angina
Markedly limits physical activity
New onset angina
More frequent, longer in duration or occurs with less exertion than previous angiina
Increasing angina
Symptoms of acute coronary syndrome
Prolonged pain Usually retrosternal location, radiating to the left chest, arm Nausea, vomiting Palpitations Diaphoresis Sense of impending doom
Acute coronary syndrome
STEMI
NSTEMI
US
Risk factors of ACS
Advanced age Smoking Hypertension DM Dyslipidemia Family history of early MI Known CAD
PE of ACS
Anxious and restless Pallor with cold sweats and cold extermities Sympathetic hyperactivity 3th and 4th heart sound Friction rub Signs of congestion
If ST deviations are on V3, V4, then the problem is at the ____
LAD, anterior of the heart
If ST deviations are on V5, V6, the problem is at the _____
LCX, lateral of the heart
If ST deviation is on II, III and aVF, then the patient has _______
Right coronary artery problem
Established CAD by angiography, history of CABG or PCI, history of MI, CHF, Multiple CAD risk factors are likely to have _____
US/NSTEMI
Normal or nonspecific ST T wave changes
ST depression
T wave inversion
US/NSTEMI
Cardiac markers for US/NSTEMI
Cardiac troponin I and T
CK-MB (4-6 hours)
Diagnostic approach to US/NSTEMI
ECG, Cardiac markers, Treadmill exercise testing, CT angiogram
TIMI Risk stratification
Age >/= 65 years >/= 3 CAD risk factors Prior stenosis >50% ST deviation >/= 2 anginal events = 24h ASA in last 7 days Elevated cardiac markers
Pharma intervention for plaque rupture
Statins
Pharma intervention for platelet adhesion
ASA, clopidogel, GP IIb/IIa inhibitors
Pharma intervention for activation of clotting cascade
Anticoagulant agents
Pharma intervention for myocardial ischemia
Beta blockers
Nitrates
Calcium antagonists
Treatment of US/NSTEMI
Bed rest Nirates B-blockers CCB Morphine sulfate
Limited by hypotension and bradycardia
CI if with pulmonary congestion and severe reactive airways disease
Beta-blockers (metaprolol)
Used when betablockers are not effective
CCB (Diltiazem, verapamil)
Used for persistent angina
Morphine sulfate
Prevent the progression of intracoronary thrombi
Promote stabilization of the atherosclerostic plaque, thereby reducing myocardial ischemia and preventing further complications such as death or MI
Antithrombotic therapy
Antiplatelet drugs
Aspirin Clopidogrel GP IIb/IIa antagonists (Abciximab, eptifibatie, tirofiban) Prasugrel Ticagrelor
Only for PCI patients
Prasugrel
Reduced mortality
Increased risk of bleeding
Reversible
Ticagrelor
Anticoagulant agents
Unfractioned heparin
Low molecular weight heparin (Enoxaparin)
Fondaparinux
Bivalirudin
Standard therapy, continuous IV infusion
Requires periodic monitoring of prothrombin time
To prolong pTT
Unfractioned heparin
Longer acting
Subcutaneous administration
No need for PTT monitoring
Low molecular weight heparin (enoxaparin)
Once a day administration
Less bledding than enoxaparin
Direct factor X inhibitor
Fondaparinux
Direct thrombin inhibitor
Bivalirudin
Indications for use of an early invasive strategy in patients with NSTEMI
Recurrent angina at rest/low-level activity despite treatment Elevated TnT or TnI New ST-segment depression CHF symptoms, rales MR EF < 0.40 SustainedVT PCI < 6 months, prior CABG High risk findings from noninvasive testing Hemodynamic instability Mild-to-moderate renal dysfunction DM High TIMI Risk SCore (>3)
In coronary angiogram, catheter is introduced either via the ____ or ____
Brachial artery
Femoral artery
Coronary angioplasty/stenting
Stent insertion
Stent expansion
Stent remains in the coronary artery
Stent has a drug coating that controls recovery to prevent re-narrowing
Drug-eluting stents
Long term management for UA/NSTEMI
ASA Clopidogrel Statins ACEI or ARB (LV remodeling) Lifestyle modification
Ischemic pain at rest caused by spasm of the coronary artery
Transient ST elevation on ECG
Hypercontractility of vascular smooth muscle
Prinzmetal angina
Treatment of Prinzmetal angina
Smoking cessation
Calcium antagonists
Addition of long acting nitrates to CCb
Detection of rise and fall of cardiac biomarker valus with at least one value above the 99th upper reference limit and at least one of the following: symptoms of ischemia, new or presumed new significant ST segment T wave changes or new left bundle branch block, development of pathologic Q waves in ECG, imaging evidence, identification of an intracoronary thrombus
AMI
Spontaneous MI
Type 1
MI secondar to ischemic imbalance
Type 2
MI resulting in death when biomarkers aren’t available
Type 3
MI related to PCI
Type 4a
MI related to stent thrombosis
Type 4b
Mi related to CABG
Type 5
Symptoms associated with AMI
Prolonged pain Usually retrosternal location, radiating to left chest, arm Nausea/vomiting Palpitations Diaphoresis Sense of impending doom
In distress, levine sign HR, pulse, RR variable BP variable Low-grade fever Examination of JVP Pulmonary crackles S4 gallop S3 gallop Murmurs
STEMI
Useful adjunct for chest pain patient with non-diagnostic or uninterpretable ECG
Can identify regional wall motion
2D echo
Early presentation
Invasive strategy not an option
Delay to stratery > prolonged transport, door-to-balloon time > 90 minutes
Fibrinolysis
Skilled PCI lab available with surgical back-up Door-to-balloon time < 90 minutes High risk patients Late presentation STEMI diagnosis in doubt
Primary PCI
General measures to address STEMI
Morphine
Oxygen
Aspirin
Nitrate
Main goal of fibrinolytic therapy
Full coronary patency
Reduces infarct size, limits LV dysfunction, and reduces incidence of serious complications: septal rupture, cardiogenic shock, malignant ventricular arrhythmias
Fibrinolytic therapy
Absolute CI of fibrinolytic therapy
Hx of cardiovascular hermorrhage CVA within the past year BP > 180 systolic or 110 diastolic Aortic dissection Active internal bledding
Relative CI of fibrinolytic therapy
Current anticoagulant use Invasive surgery within 2 weeks Prolonged CPR Known bleeding diathesis Hemorrhagic opthalmic condition Active peptic ulcer disease Sever HTN concurrently actively controlled
Most frequent and potentially most serious complication of fibrinolytic therapy
Hemorrhage
Reduce mortality after STEMI
Greatest benefit in patients with large anterior infarctions prior M, globally reduced LV systolic function
Reduces ventricular remodeling and subsequent risk of congestive heart failure
ACE or ARBs
Complication of STEMI common in patients with multi-vessel disease
Managements include vasopressors/inotropes, inaortic balloon counter pulsation, early reperfusion/revascularization
Cardiogenic shock
1/3 of inferior wall MI have _____, commonly manifested as hypotension, distended neck veins, clear lung fields. In ECG; ST elevation on right sided precordial leads, In 2D echo: RV dilatation and dysfunction
Right ventricular infarction
Treatment of right ventricular infarction
Volume expansion to improve LV filling
Pericarditis post MI
Dressler syndrome
Complication of STEMI that may lead to stroke
Thromboembolism
What to give to patients with ventricular premature beats
Beta-blockers
One of the worst complications of STEMI
Can occur within the first 24 hours of STEMI without warning arrhythmias
Ventricular fibrillation/tachycardia
Treatment for sustained VT
IV amiodarone
Treatment for VF or hemodynamically unstable VT
DC cardioversion
Treatment for VF/VT after 48 hours
ICD/Defib
Post infaction risk stratification and management
Submaximal stress test (hospital) or full stress test (4-6 w after discharge)
2D echo to assess LV systolic function
Secondary prevention of STEMI
Antiplatelet therapy AC-I, ARB B-blockers Statin therapy Risk factor modification